Skip to main content

Table 3 Predictive factors for proteinuria decrementa after 24 weeks of valsartan treatment

From: Urinary angiotensinogen as a surrogate marker predicting the antiproteinuric effects of angiotensin receptor blockers in patients with overt proteinuria: a multicenter prospective study

 

Univariable

Multivariable

OR

95% CI

P

OR

95% CI

P

History of hypertension

1.150

0.608–2.174

0.667

   

History of DM

2.105

1.005–4.411

0.049

2.091

0.964, 4.536

0.062

Previous RAS inhibitor use

0.651

0.354–1161

0.143

   

MAP (mmHg)

1.007

0.981–1.003

0.600

   

eGFR (mL/min/1.73m2)

1.006

 

0.256

   

Baseline ln(uAGT/Cr) (μg/g)

1.387

1.082–1778

0.010

1.338

1.035, 1.729

0.026

Baseline ln(uR/Cr) (pg/g)

1.199

1.022–1.407

0.026

1.073

0.901, 1.278

0.430

ΔuNa/Cr (mmol/mmol)b

0.877

0.693–1.111

0.227

   
  1. Abbreviations: CI confidence interval, DM diabetes mellitus, eGFR estimated glomerular filtration rate, MAP mean arterial pressure, OR odds ratio, RAS renin angiotensin system, uAGT/Cr urinary angiotensinogen/creatinine ratio, uNa/Cr urinary sodium/creatinine ratio, uPCR urinary protein/creatinine ratio, uR/Cr urinary renin/creatinine ratio
  2. Multivariable logistic regression analysis was conducted with variables with P < 0.1 in the univariable models
  3. aProteinuria decrement: decrease in uPCR ≥ 1 mg/mg
  4. bΔuNa/Cr = [uNa/Cr at 24 weeks] - [baseline uNa/Cr]
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us